Could a nasal spray fight Alzheimer's? early trial begins

NCT ID NCT07187141

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early study tested a nasal spray called Protollin in 16 people with early Alzheimer's disease. The main goal was to see if it is safe and tolerable. The spray is designed to boost the immune system in the brain, possibly helping to clear away harmful proteins linked to Alzheimer's.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Protollin (nasal spray)

What this could lead to

If safe and effective, this could point toward a new way to treat Alzheimer's by stimulating the immune system to clear harmful proteins from the brain.

What could go wrong

This is a very early, small Phase 1 trial focused only on safety, not on whether the drug works. Many promising early treatments fail in later, larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States